Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

ERRγ agonist under mechanical stretching manifests hypertrophic cardiomyopathy phenotypes of engineered cardiac tissue through maturation.

Stem cell reports - 14 Nov 2023

Fujiwara Yuya, Miki Kenji, Deguchi Kohei, Naka Yuki, Sasaki Masako, Sakoda Ayaka, Narita Megumi, Imaichi Sachiko, Sugo Tsukasa, Funakoshi Shunsuke, Nishimoto Tomoyuki, Imahashi Kenichi, Yoshida Yoshinori

Abstract excerpt

Engineered cardiac tissue (ECT) using human induced pluripotent stem cell-derived cardiomyocytes is a promising tool for modeling heart disease. However, tissue immaturity makes robust disease modeling difficult. Here, we established a method for modeling hypertrophic cardiomyopathy (HCM) malignant (MYH7 R719Q) and nonmalignant (MYBPC3 G115∗) pathogenic sarcomere gene mutations by accelerating ECT maturation...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cardiomyopathy, Hypertrophic
Share to Carrier Proteins

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hypertrophy

Share to Induced Pluripotent Stem Cells

Share to Mutation

Share to Myocytes, Cardiac

Share to Phenotype

Share to Tissue Engineering

Source

Open in PubMed Open full text

Identifiers

PMID: 37802074
DOI: 10.1016/j.stemcr.2023.09.003
PMCID: PMC10679535

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

ERRγ agonist under mechanical stretching manifests hypertrophic cardiomyopathy phenotypes of engineered cardiac tissue through maturation.PMID 37802074Read ↗

Maturation of human induced pluripotent stem cell-derived cardiomyocytes for modeling hypertrophic cardiomyopathySemantic proximity Read ↗

CRISPR/Cas9 editing in human pluripotent stem cell-cardiomyocytes highlights arrhythmias, hypocontractility, and energy depletion as potential therapeutic targets for hypertrophic cardiomyopathySemantic proximity Read ↗

Bioengineering Approaches to Mature Human Pluripotent Stem Cell-Derived CardiomyocytesSemantic proximity Read ↗

Human engineered cardiac tissue model of hypertrophic cardiomyopathy recapitulates key hallmarks of the disease and the effect of chronic mavacamten treatmentSemantic proximity Read ↗

Length-dependent hypercontractility decoupled from cellular adaptations is the initial phenotype in MYBPC3-haploinsufficient iPSC-derived engineered cardiac tissuesSemantic proximity Read ↗

Maturation of Pluripotent Stem Cell-Derived Cardiomyocytes Enables Modeling of Human Hypertrophic CardiomyopathySemantic proximity Read ↗

A Contraction Stress Model of Hypertrophic Cardiomyopathy due to Sarcomere MutationsSemantic proximity Read ↗

Modeling Human Cardiac Hypertrophy in Stem Cell-Derived CardiomyocytesSemantic proximity Read ↗

Progressive developmental cues from multiple cardiac cell types promote cardiomyocyte maturationSemantic proximity Read ↗

Long-term mavacamten exposure reduces force and sarcomere density in a hiPSC model of hypertrophic cardiomyopathySemantic proximity Read ↗

Transcriptomics reveal stretched human pluripotent stem cell-derived cardiomyocytes as an advantageous hypertrophy modelSemantic proximity Read ↗

Current methods for the maturation of induced pluripotent stem cell-derived cardiomyocytesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.